Alnylam Pharmaceuticals Inc (ALNY)vsBeiGene, Ltd. (ONC)
ALNY
Alnylam Pharmaceuticals Inc
$174.00
-25.13%
HEALTHCARE · Cap: $31.10B
ONC
BeiGene, Ltd.
$371.56
-0.48%
HEALTHCARE · Cap: $42.96B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 28% more annual revenue ($6.13B vs $4.80B). ALNY leads profitability with a 16.1% profit margin vs 10.7%. ALNY appears more attractively valued with a PEG of 0.29. ALNY earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy68
out of 100
Grade: B-
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.3%
Fair Value
$2546.59
Current Price
$174.00
$2372.59 discount
Margin of Safety
+79.6%
Fair Value
$1720.81
Current Price
$371.56
$1349.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 60 in profit
Revenue surging 66.9% year-over-year
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 17.2x book value
0.0% earnings growth
Distress zone — elevated risk
Trading at 8.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Profitability is solid with margins at 16.1% and operating margin at 17.9%. Revenue growth of 66.9% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are P/E Ratio, Price/Book, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 67.5x leaves little room for execution misses.
Key Dynamics to Monitor
ONC carries more volatility with a beta of 0.61 — expect wider price swings.
ALNY is growing revenue faster at 66.9% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (68/100 vs 64/100), backed by strong 16.1% margins and 66.9% revenue growth. ONC offers better value entry with a 79.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?